| __timestamp | Amphastar Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 19586000 |
| Thursday, January 1, 2015 | 37065000 | 29135000 |
| Friday, January 1, 2016 | 41199000 | 42791000 |
| Sunday, January 1, 2017 | 43415000 | 49577000 |
| Monday, January 1, 2018 | 57564000 | 89209000 |
| Tuesday, January 1, 2019 | 68853000 | 69099000 |
| Wednesday, January 1, 2020 | 67229000 | 75961000 |
| Friday, January 1, 2021 | 60932000 | 90467000 |
| Saturday, January 1, 2022 | 74771000 | 74552000 |
| Sunday, January 1, 2023 | 73741000 | 91593000 |
Cracking the code
In the competitive world of pharmaceuticals, innovation is the key to staying ahead. Over the past decade, Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc. have been at the forefront of this race, investing heavily in research and development (R&D). From 2014 to 2023, Supernus consistently outpaced Amphastar, with an average R&D expenditure of approximately $63 million annually, compared to Amphastar's $55 million. Notably, in 2023, Supernus invested 24% more in R&D than Amphastar, highlighting its commitment to innovation. This trend underscores the strategic priorities of these companies, with Supernus focusing more aggressively on developing new therapies. As the pharmaceutical landscape evolves, these investments could be pivotal in determining market leadership and the development of groundbreaking treatments.
Who Prioritizes Innovation? R&D Spending Compared for Zoetis Inc. and Amphastar Pharmaceuticals, Inc.
Comparing Innovation Spending: argenx SE and Supernus Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Summit Therapeutics Inc. vs Supernus Pharmaceuticals, Inc.
Comparing Innovation Spending: Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Grifols, S.A. and Amphastar Pharmaceuticals, Inc. Allocate Funds
Corcept Therapeutics Incorporated or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: ADMA Biologics, Inc. and Supernus Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CymaBay Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Comparing Innovation Spending: Rhythm Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc. or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?